Defining the Need for Translational Guidance on Cell Therapy in Stroke
Defining the Need for Translational Guidance on Cell Therapy in Stroke
复制标题
DOI：
--
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Theo Diamandis;C. Borlongan
中科院分区：
文献类型：
--
作者：
Theo Diamandis;C. Borlongan
Many clinical trials have failed, despite positive laboratory findings. Stroke clinical trials are no exception, with tissue-type plasminogen activator still the only effective drug for stroke with limited therapeutic window. To enhance the successful outcome of novel therapies in the clinic, initiatives for translational research guidelines have been pursued. In particular, the advancement of stem cell therapy for stroke from the laboratory to the clinic has now been guided by a set of recommendations called Stem Cell Therapeutics as an Emerging Paradigm for Stroke (STEPS). We review here the major criteria for preclinical studies of stem cells arising from the 3 STEPS meetings in an effort to emphasize the need for careful and rigorous assessment of the safety, efficacy, and mechanism of action associated with stem cell therapy for stroke further. Learning from our previous mistakes and identifying gaps in knowledge will likely prevent stem cell therapy from becoming yet another statistic of failed clinical trial in stroke.
